Globus MedicalMEX:GMED 92 ROE % is 10.69% as of Mar. 2026, which is 5% below its 10-year median of 11.27. GuruFocus rates MEX:GMED with a GF Score™ of 92/100 and a GF Value™ of MXN1,721.21 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 797 Medical Devices & Instruments companies, Globus Medical ranks better than 82.56% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Globus Medical's annualized net income for the quarter that ended in Mar. 2026 was MXN8,966 Mil. Globus Medical's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was MXN83,840 Mil. Therefore, Globus Medical's annualized ROE % for the quarter that ended in Mar. 2026 was 10.69%.
The historical rank and industry rank for Globus Medical's ROE % or its related term are showing as below:
MEX:GMED'
s ROE % Range Over the Past 10 Years
Min: 2.52 Med: 11.27 Max: 14.53
Current: 13.28
During the past 13 years, Globus Medical's highest ROE % was 14.53%. The lowest was 2.52%. And the median was 11.27%.
MEX:GMED's ROE % is ranked better than 82.56% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs MEX:GMED: 13.28
Globus Medical (MEX:GMED) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Globus Medical ROE % Related Terms
Globus Medical ROE % Historical Data
* Premium members only.
The historical data trend for Globus Medical's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Globus Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Globus Medical ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Globus Medical's ROE % distribution charts can be found below:
* The bar in red indicates where Globus Medical's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Globus Medical (MEX:GMED) has a ROE % of 10.69% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Globus Medical and its competitors. This is near median its historical median of 11.27. Over the past decade, Globus Medical's ROE % has ranged from 2.52 to 14.53. According to the industry distribution chart, Globus Medical ranks #139 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 17.4%.
Is Globus Medical's ROE % too high?
Globus Medical's current ROE % of 10.69% is near median its 10-year median of 11.27. Over the past 10 years, this metric has ranged from a low of 2.52 to a high of 14.53. The Medical Devices & Instruments industry median ROE % is 2.40. Globus Medical's value of 10.69% is 345.4% above this industry median. Based on the distribution chart, Globus Medical ranks #139 out of 797 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Globus Medical has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Globus Medical's ROE % compare to PEN and PODD?
According to the Medical Devices & Instruments industry distribution chart, Globus Medical ranks #139 out of 797 companies for ROE %. This places Globus Medical in the top 17% of its industry — outperforming the majority of peers. The industry median ROE % is 2.40. Globus Medical's value of 10.69% is 345.4% above this benchmark. Historically, Globus Medical's own ROE % has ranged from 2.52 to 14.53 over the past decade. While the company's 10-year median is 11.27 vs. the industry median of 2.40, Globus Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.40, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Globus Medical's current ROE % of 10.69% is 345.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Globus Medical and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Globus Medical's current ROE % is 10.69%, which is near median its own 10-year median of 11.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Globus Medical stock overvalued right now?
Based on GuruFocus' analysis, Globus Medical (MEX:GMED) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN1,721.21, compared to a current price of MXN1,465.00 — trading 14.9% below its estimated fair value. The current ROE % is 10.69%, which is near median its 10-year median of 11.27 and 345.4% above the Medical Devices & Instruments industry median of 2.40. Globus Medical's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Globus Medical (MEX:GMED), the current ROE % is 10.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Globus Medical (MEX:GMED) Overvalued in 2026?
Based on GuruFocus' analysis, Globus Medical stock appears to be undervalued.
The current stock price of MXN1,465.00 is trading 14.9% below its estimated GF Value™ of MXN1,721.21.
GuruFocus considers Globus Medical to be Modestly Undervalued.
Key valuation signals for MEX:GMED:
ROE %: 10.69% (near median its 10-year median of 11.27)
GF Value™: MXN1,721.21 vs. price of MXN1,465.00 (14.9% below fair value)
Industry Position: 345.4% above the Medical Devices & Instruments median (#139 of 797)
No single metric tells the full story. See the MEX:GMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
92GF Score
Get the complete analysis for MEX:GMED
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GMED has been successfully added to your 
